<DOC>
	<DOCNO>NCT01491087</DOCNO>
	<brief_summary>The study assess safety Pentaxim® vaccine three-dose primary vaccination 2 , 3 , 4 month age order meet regulatory requirement license renewal product register China , generate additional clinical data use three-dose primary vaccination schedule Chinese province . Primary Objective - To describe safety administration PENTAXIM® 2 , 3 , 4 month age study population .</brief_summary>
	<brief_title>Safety PENTAXIM® Given Three-Dose Primary Vaccination 2 , 3 , 4 Months Age Infants China</brief_title>
	<detailed_description>Each study participant receive injection PENTAXIM® 2 , 3 , 4 month age monitor safety entire study period . The duration participant trial approximately 3 4 month .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 month ( 60 74 day ) inclusive day first study visit Informed consent form sign dated parent ( ) legally acceptable representative Subject parent/legally acceptable representative able attend schedule visit comply trial procedure . Participation plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy since birth , longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week since birth ) Known systemic hypersensitivity vaccine component , history life threaten reaction vaccine use trial vaccine contain substance Clinically significant illness , accord investigator judgment , stage could interfere trial conduct completion Evolving encephalopathy Receipt immune globulin , blood bloodderived product since birth Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis disease Haemophilus influenzae type b infection Receipt vaccine 14 day precede first trial vaccination plan receipt vaccine 14 day follow first trial vaccination Acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( axillary temperature ≥37.1°C ) . A prospective subject include study condition resolve febrile event subside . Contraindications vaccination accord PENTAXIM® summary product characteristic ( SPC ) leaflet In emergency setting , hospitalize involuntarily Identified natural adopt child Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>74 Days</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Pentaxim®</keyword>
	<keyword>Whole-cell Pertussis vaccine</keyword>
	<keyword>Acellular Pertussis vaccine</keyword>
	<keyword>Haemophilus influenzae type b polysaccharide</keyword>
	<keyword>Inactivated Polio vaccine</keyword>
	<keyword>Pentavac®</keyword>
</DOC>